Q-omics provides the consensus-scored MED31 profile across patient tissues and cancer cell-line models. MED31 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MED31 is differentially expressed in 7, with the highest sampling consensus in LIHC. Additionally, MED31 protein abundance shows 19,811 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, LIHC, and LSCC as cancer lineages where MED31 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MED31 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MED31 survival associations across molecular data types. MED31 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MED31 RNA expression–survival associations across cancer types. High MED31 expression shows unfavorable associations in UVM, KICH, LGG, LIHC, SCLC and BLCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for MED31 RNA expression.
This table summarizes MED31 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 8. The strongest signals are observed in LIHC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MED31. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MED31 shows lower tumor expression in KICH and higher tumor expression in LIHC, HNSC, BLCA, CHOL and ESCA. The LIHC box plot shows higher MED31 RNA expression in tumor versus normal tissue (log2 FC = +0.679, t-test p < 0.001).
This table shows molecular features associated with MED31 in patient tissues and cancer cell lines. In patient samples, MED31 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MED31 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and UPPER_AERODIGESTIVE_TRACT.
